These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28085283)

  • 21. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
    Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
    Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of
    Iyer MR; Cinar R; Coffey NJ; Kunos G
    J Labelled Comp Radiopharm; 2018 May; ():. PubMed ID: 29790591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1,3,4-Thiadiazole derivatives as selective inhibitors of iNOS versus nNOS: Synthesis and structure-activity dependence.
    López-Cara LC; Carrión MD; Entrena A; Gallo MA; Espinosa A; López A; Escames G; Acuña-Castroviejo D; Camacho ME
    Eur J Med Chem; 2012 Apr; 50():129-39. PubMed ID: 22336385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
    Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK
    J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia.
    Lin CY; Hsu YJ; Hsu SC; Chen Y; Lee HS; Lin SH; Huang SM; Tsai CS; Shih CC
    J Mol Cell Cardiol; 2015 Aug; 85():249-61. PubMed ID: 26093151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Part 1: synthesis and biological evaluation of dihydropyridin-2-imines.
    Kawanaka Y; Kobayashi K; Kusuda S; Tatsumi T; Murota M; Nishiyama T; Hisaichi K; Fujii A; Hirai K; Naka M; Komeno M; Nakai H; Toda M
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2291-4. PubMed ID: 12161118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endogenous cannabinoid system regulates intestinal barrier function in vivo through cannabinoid type 1 receptor activation.
    Zoppi S; Madrigal JL; Pérez-Nievas BG; Marín-Jiménez I; Caso JR; Alou L; García-Bueno B; Colón A; Manzanares J; Gómez-Lus ML; Menchén L; Leza JC
    Am J Physiol Gastrointest Liver Physiol; 2012 Mar; 302(5):G565-71. PubMed ID: 22135307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological evaluation of 4,5-dihydro-1H-pyrazole derivatives as potential nNOS/iNOS selective inhibitors. Part 2: Influence of diverse substituents in both the phenyl moiety and the acyl group.
    Carrión MD; Chayah M; Entrena A; López A; Gallo MA; Acuña-Castroviejo D; Camacho ME
    Bioorg Med Chem; 2013 Jul; 21(14):4132-42. PubMed ID: 23735830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use.
    Liu P; Lin LS; Hamill TG; Jewell JP; Lanza TJ; Gibson RE; Krause SM; Ryan C; Eng W; Sanabria S; Tong X; Wang J; Levorse DA; Owens KA; Fong TM; Shen CP; Lao J; Kumar S; Yin W; Payack JF; Springfield SA; Hargreaves R; Burns HD; Goulet MT; Hagmann WK
    J Med Chem; 2007 Jul; 50(15):3427-30. PubMed ID: 17608398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a series of aminopiperidines as novel iNOS inhibitors.
    Le Bourdonnec B; Leister LK; Ajello CA; Cassel JA; Seida PR; O'Hare H; Gu M; Chu GH; Tuthill PA; DeHaven RN; Dolle RE
    Bioorg Med Chem Lett; 2008 Jan; 18(1):336-43. PubMed ID: 18024030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models.
    Payne JE; Bonnefous C; Symons KT; Nguyen PM; Sablad M; Rozenkrants N; Zhang Y; Wang L; Yazdani N; Shiau AK; Noble SA; Rix P; Rao TS; Hassig CA; Smith ND
    J Med Chem; 2010 Nov; 53(21):7739-55. PubMed ID: 20931971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
    Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
    Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.
    Jourdan T; Demizieux L; Gresti J; Djaouti L; Gaba L; Vergès B; Degrace P
    Hepatology; 2012 Mar; 55(3):790-9. PubMed ID: 21987372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The therapeutic potential of second and third generation CB
    Cinar R; Iyer MR; Kunos G
    Pharmacol Ther; 2020 Apr; 208():107477. PubMed ID: 31926199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and characterization of a novel class of coumarin-based inhibitors of inducible nitric oxide synthase.
    Jackson SA; Sahni S; Lee L; Luo Y; Nieduzak TR; Liang G; Chiang Y; Collar N; Fink D; He W; Laoui A; Merrill J; Boffey R; Crackett P; Rees B; Wong M; Guilloteau JP; Mathieu M; Rebello SS
    Bioorg Med Chem; 2005 Apr; 13(8):2723-39. PubMed ID: 15781384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and SAR of 1,4,5,6-tetrahydropyridazines as potent cannabinoid CB1 receptor antagonists.
    Lange JH; den Hartog AP; van der Neut MA; van Vliet BJ; Kruse CG
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5675-8. PubMed ID: 19699640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
    Muccioli GG; Wouters J; Charlier C; Scriba GK; Pizza T; Di Pace P; De Martino P; Poppitz W; Poupaert JH; Lambert DM
    J Med Chem; 2006 Feb; 49(3):872-82. PubMed ID: 16451053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action.
    Degroot A; Köfalvi A; Wade MR; Davis RJ; Rodrigues RJ; Rebola N; Cunha RA; Nomikos GG
    Mol Pharmacol; 2006 Oct; 70(4):1236-45. PubMed ID: 16855179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The peripheral cannabinoid receptor 1 antagonist VD60 efficiently inhibits carbon tetrachloride-intoxicated hepatic fibrosis progression.
    Wei Y; Kang XL; Wang X
    Exp Biol Med (Maywood); 2014 Feb; 239(2):183-92. PubMed ID: 24459189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinazolinones, Quinazolinthiones, and Quinazolinimines as Nitric Oxide Synthase Inhibitors: Synthetic Study and Biological Evaluation.
    Camacho ME; Chayah M; García ME; Fernández-Sáez N; Arias F; Gallo MA; Carrión MD
    Arch Pharm (Weinheim); 2016 Aug; 349(8):638-50. PubMed ID: 27328401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.